On 10 October 2024, LigaChem and Ono announced two agreements: worldwide development of the L1CAM-targeting candidate LCB97 and research to create further ADCs with ConjuAll. The candidate became ONO-7429, received Japanese clinical permission in April 2026 and entered a Phase 1 study on 19 June.

Yong-Zu Kim's LigaChem supplied both a designed cancer candidate and chemistry for developing others. Ono research executive Seishi Katsumata wanted the package to strengthen an expanding oncology portfolio. The later trial start shows the named candidate moving into patients under Ono's sponsorship. That concrete progression is the commercial achievement so far: a preclinical licence has become an operating development programme, while the additional-target collaboration remains a separate source of possible candidates and payments.

The agreements pay LigaChem for different work. LCB97 carries up to USD700 million in upfront and success-dependent milestones, plus royalties; the upfront split is undisclosed. The separate target-selection collaboration has its own fees, milestones and royalties. Ono obtained both a candidate to advance and a way to commission more, while LigaChem's team continued supplying the underlying design expertise.

Kim and Katsumata Paired a Cancer Candidate With a Research Agreement

LigaChem chief executive Yong-Zu Kim and Ono discovery and research executive Seishi Katsumata announced their two-part relationship on 10 October 2024. Kim wanted to bring his company's ADC technology to patients worldwide through a partner with oncology experience. Katsumata wanted new treatment options for solid tumours and a stronger cancer portfolio.

The first agreement concerned LCB97, an antibody-drug conjugate that LigaChem had already designed with ConjuAll. It targets L1 cell adhesion molecule, L1CAM, reported to be highly expressed in several solid tumours. LigaChem's experiments had shown anti-tumour effects in mouse cancer models. The partners were choosing a preclinical construct to develop, before human safety or activity was established.

The second agreement kept the research relationship open to further candidates against targets selected by Ono. That combination was attractive for different reasons on each side. Kim's team could contribute both an existing design and the methods behind it; Katsumata's organisation could begin with a defined product while deciding where to apply those methods next.

ConjuAll Offered Ono Further Targets, Not Every LigaChem Asset

An ADC links an antibody that recognises a target to a cytotoxic payload. The complete design has to reach the tumour and release its drug in a useful way. For LCB97, Ono obtained exclusive worldwide development, manufacture and commercialisation rights for solid tumours. It was taking responsibility for a particular candidate assembled around L1CAM.

The companies described three elements of ConjuAll: site-specific stable bioconjugation, cancer-selective linker activation and cancer-selective activation of the payload. These are their explanation of the platform's intended advantages. The aim is to combine potency with selective delivery and activation, reducing damage outside the tumour. The claimed wider therapeutic window still needs assessment in each resulting clinical medicine.

The additional-target work begins at an earlier point, with Ono selecting targets for new designs. Those resulting candidates carry target-specific exclusive global rights and their own compensation. LigaChem was not selling every ConjuAll application: it was giving Ono a defined route to build more ADCs with the platform. The package linked a product decision with a continuing discovery relationship.

Ono Had Already Bought a US-European Oncology Organisation

Ono's worldwide ambitions were taking organisational form before the LigaChem signing. Its April 2024 agreement to acquire Deciphera valued that transaction at about USD 2.4 billion. On 11 June, Ono confirmed completion of the tender offer and merger, making Deciphera a wholly owned subsidiary. The acquisition had closed four months before the ADC package was announced.

Ono chairman and chief executive Gyo Sagara linked the completed purchase to Deciphera's cancer research capabilities and commercial presence in Europe and the United States. Deciphera chief executive Steven Hoerter welcomed the new ownership. This was a separate acquisition of an operating company and its organisation, unlike the licensing of a preclinical candidate from LigaChem.

That timing gives the Korean licence a concrete industrial setting. Ono was extending its cancer pipeline while acquiring an organisation able to serve markets outside Japan. Its new LigaChem relationship supplied a different kind of oncology research from Deciphera's kinase programmes. Ono's worldwide development and commercialisation rights for LCB97 fitted that expanding international oncology programme.

Japanese Cancer Centres Began Testing ONO-7429 In 2026

In April 2026, LigaChem recorded Japanese Phase 1 permission for LCB97, now ONO-7429. Ono began its first study on 19 June. The sponsor's August update listed recruiting centres including National Cancer Center Hospital East in Kashiwa, Gunma University Hospital and Osaka International Cancer Institute. The candidate had moved from the companies' laboratories into a clinical development programme.

The open-label dose-escalation study is for adults with unresectable advanced or recurrent solid tumours who cannot tolerate or have not responded to standard therapy. Ono plans eighty participants. Its first task is to establish safety and tolerability, including dose-limiting toxicities, while measuring drug exposure and looking for tumour activity. There is no control arm.

Those choices fit the candidate's early stage. The team needs to learn what doses can be given and how the ADC behaves in people before pursuing a later development programme. L1CAM provides the targeting rationale, but the linked antibody and payload must work together safely in the patient population under investigation.

Ono estimates primary completion in July 2028 and overall completion in March 2030. For now, the significant change is the study itself: the construct Kim's team licensed has reached human investigation under its partner's sponsorship. The separate ConjuAll research gives the relationship another path beyond this first candidate, while ONO-7429 proceeds on its own clinical timetable.

DSML research · 8 October 2026 · Revised 31 October 2026